Tag: omalizumab

• Cassius Thornfield
• 0

Chronic spontaneous urticaria affects millions who don’t respond to antihistamines. In 2026, second-line treatments like omalizumab, remibrutinib, and dupilumab offer real hope-with new oral options changing the game.